The manufacturer of Austedo XR is Teva Pharmaceuticals [1].
What is Austedo XR and what is it used for?
Austedo XR is a prescription medication used to treat chorea associated with tardive dyskinesia and Huntington's disease [1]. It is an extended-release formulation [2].
How does Austedo XR work?
Austedo XR contains deutetrabenazine, which works by affecting certain natural chemicals in the brain called neurotransmitters [2]. Specifically, deutetrabenazine is a selective, reversible inhibitor of vesicular monoamine transporter 2 (VMAT2) [3]. This mechanism helps to reduce the involuntary movements associated with tardive dyskinesia and Huntington's disease [3].
When does Austedo XR's patent expire?
Information regarding the specific patent expiry dates for Austedo XR is available through resources like DrugPatentWatch.com [4]. Patent information can be complex, involving multiple patents and potential challenges [4].
What are the side effects of Austedo XR?
Common side effects of Austedo XR can include drowsiness, fatigue, insomnia, nausea, and nasopharyngitis [1]. A serious potential side effect is depression and suicidal thoughts, and patients should be monitored for these symptoms [1].
Who are Austedo XR's competitors?
In the treatment of tardive dyskinesia, Austedo XR competes with other medications that target VMAT2, such as Ingrezza (valbenazine) [3]. For Huntington's disease, Austedo XR is a primary treatment option, though research into other therapeutic approaches continues [3].
What is the difference between Austedo and Austedo XR?
Austedo is the immediate-release formulation of deutetrabenazine, while Austedo XR is the extended-release formulation [2]. The extended-release version allows for less frequent dosing [2].